Brokerages expect that Intersect ENT (NASDAQ:XENT) will report sales of $23.68 million for the current fiscal quarter, Zacks reports. Nine analysts have made estimates for Intersect ENT’s earnings, with the highest sales estimate coming in at $24.12 million and the lowest estimate coming in at $23.48 million. Intersect ENT reported sales of $20.47 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 15.7%. The firm is expected to announce its next quarterly earnings report on Tuesday, May 1st.
On average, analysts expect that Intersect ENT will report full-year sales of $115.11 million for the current year, with estimates ranging from $112.70 million to $118.70 million. For the next fiscal year, analysts expect that the company will report sales of $146.96 million per share, with estimates ranging from $137.30 million to $160.97 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Intersect ENT.
Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.06. The company had revenue of $29.53 million during the quarter, compared to analyst estimates of $29.45 million. Intersect ENT had a negative return on equity of 14.40% and a negative net margin of 16.99%.
In related news, insider Lisa D. Earnhardt sold 11,166 shares of the business’s stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $33.47, for a total transaction of $373,726.02. Following the transaction, the insider now owns 495,849 shares in the company, valued at approximately $16,596,066.03. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Richard E. Kaufman sold 50,000 shares of the business’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $33.33, for a total value of $1,666,500.00. Following the transaction, the chief operating officer now owns 107,470 shares in the company, valued at approximately $3,581,975.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 130,623 shares of company stock worth $4,600,347. Company insiders own 13.70% of the company’s stock.
A number of large investors have recently made changes to their positions in the stock. Teachers Retirement System of The State of Kentucky increased its holdings in Intersect ENT by 4.1% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 42,584 shares of the medical equipment provider’s stock valued at $1,380,000 after purchasing an additional 1,696 shares during the period. Nationwide Fund Advisors increased its holdings in Intersect ENT by 4.4% during the 3rd quarter. Nationwide Fund Advisors now owns 56,901 shares of the medical equipment provider’s stock valued at $1,772,000 after purchasing an additional 2,377 shares during the period. Wells Fargo & Company MN increased its holdings in Intersect ENT by 5.5% during the 3rd quarter. Wells Fargo & Company MN now owns 51,476 shares of the medical equipment provider’s stock valued at $1,604,000 after purchasing an additional 2,666 shares during the period. Cubist Systematic Strategies LLC increased its holdings in Intersect ENT by 34.8% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 11,025 shares of the medical equipment provider’s stock valued at $343,000 after purchasing an additional 2,846 shares during the period. Finally, Oppenheimer Asset Management Inc. purchased a new position in Intersect ENT during the 3rd quarter valued at about $117,000. Institutional investors own 84.49% of the company’s stock.
NASDAQ:XENT opened at $39.55 on Monday. The firm has a market cap of $1,172.82, a P/E ratio of -70.63 and a beta of 0.75. Intersect ENT has a 52-week low of $16.00 and a 52-week high of $40.00.
COPYRIGHT VIOLATION NOTICE: “$23.68 Million in Sales Expected for Intersect ENT (XENT) This Quarter” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2018/04/16/23-68-million-in-sales-expected-for-intersect-ent-xent-this-quarter.html.
About Intersect ENT
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.